These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

49 related items for PubMed ID: 19804833

  • 1. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.
    Ammoun S, Ristic N, Matthies C, Hilton DA, Hanemann CO.
    Neurobiol Dis; 2010 Jan; 37(1):141-6. PubMed ID: 19804833
    [Abstract] [Full Text] [Related]

  • 2. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E.
    Clin Cancer Res; 2007 Mar 01; 13(5):1576-83. PubMed ID: 17332304
    [Abstract] [Full Text] [Related]

  • 3. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.
    Oncogene; 2007 Feb 08; 26(6):813-21. PubMed ID: 16909118
    [Abstract] [Full Text] [Related]

  • 4. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
    Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO.
    Cancer Res; 2008 Jul 01; 68(13):5236-45. PubMed ID: 18593924
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
    Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2002 Sep 01; 43(9):3091-8. PubMed ID: 12202534
    [Abstract] [Full Text] [Related]

  • 14. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C, Jin M, Kim HB, Lee SM, Amatya PN, Hyun JW, Chang IY, You HJ.
    Oncogene; 2009 May 28; 28(21):2173-84. PubMed ID: 19398949
    [Abstract] [Full Text] [Related]

  • 15. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.
    Blood; 2007 Sep 01; 110(5):1656-63. PubMed ID: 17510321
    [Abstract] [Full Text] [Related]

  • 16. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ, Chang LS, Welling DB, Copik AJ, Fernández-Valle C.
    Oncotarget; 2017 May 09; 8(19):31666-31681. PubMed ID: 28427224
    [Abstract] [Full Text] [Related]

  • 17. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
    Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD.
    Mol Cancer Ther; 2007 Aug 09; 6(8):2209-19. PubMed ID: 17699718
    [Abstract] [Full Text] [Related]

  • 18. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
    Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO.
    Glia; 2012 Nov 09; 60(11):1721-33. PubMed ID: 22821509
    [Abstract] [Full Text] [Related]

  • 19. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
    Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR.
    Clin Cancer Res; 2009 Nov 01; 15(21):6619-29. PubMed ID: 19843666
    [Abstract] [Full Text] [Related]

  • 20. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.
    Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van Der Graaf WT, Van Rossum MM, Van Herpen CM.
    Acta Oncol; 2010 Nov 01; 49(1):110-3. PubMed ID: 19634052
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.